RettEd Webinar: Q&A with Kathie Bishop, Chief Scientific Officer, Acadia Pharmaceuticals

In anticipation of the FDA’s priority review of Trofinetide - the first potential treatment for Rett syndrome - we know the Rett community has questions. In this video, Dr. Kathie Bishop, SVP Rare Disease, External Innovation & Chief Scientific Officer for Acadia Pharmaceuticals, answers your most frequently asked questions in conversation with IRSF CEO, Melissa Kennedy, and CSO, Dr. Dominique Pichard. Watch to learn more about the FDA’s decision timeline, how Trofinetide may treat Rett, its common side effects, and much more!

[@nicolascharles27]

Thanks a lot for the video, we learn a little more about Trofinetide. So bad that we French people have to wait for Neuren new partnerships.